Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Rigshospitalet manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 2 pending office actions currently active. These actions are being handled by 2 distinct examiners within 1 distinct art unit. SABILA, MERCY HELLEN is the busiest examiner, with 1 pending office action. The 2 pending office actions are being reviewed by 2 different examiners, but they are both within the same art unit.
This suggests a consistent technical framework for the Biotechnology & Pharmaceuticals innovations, even with different examiner perspectives. SABILA, MERCY HELLEN is responsible for 1 pending office action, which is a portion of the 2 pending office actions. Practitioners should be aware of the different styles of the 2 distinct examiners while adhering to the specific guidelines of the 1 distinct art unit to resolve the 2 pending office actions. This structure requires a tailored approach for each of the 2 pending office actions to ensure consistent progress. The presence of 2 distinct examiners ensures individual attention for each matter.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
| HA, JULIE | 1 | 75.7% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17299795 | VASODILATORS FOR USE IN THE TREATMENT OF A RETINAL ISCHEMIC DISORDER | HA, JULIE | 26d overdue |
| 18034407 | SITE-SELECTIVE MODIFICATION OF PROTEINS | SABILA, MERCY HELLEN | 22d overdue |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18034407 | SITE-SELECTIVE MODIFICATION OF PROTEINS | SABILA, MERCY HELLEN | 1654 | §103 | Final Rejection | 22d overdue | Pending | Apr 28, 2023 |
| 17299795 | VASODILATORS FOR USE IN THE TREATMENT OF A RETINAL ISCHEMIC DISORDER | HA, JULIE | 1654 | §102§103§112 | Final Rejection | 26d overdue | Pending | Jun 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial